29.9 C
New York
Saturday, June 6, 2026

Tag: drug delivery

newssourceFORcompanyinformationcontent1marketreleases

Seer Files Definitive Proxy Materials and Mails Letter to Stockholders

Reinforces Seer’s Clear Strategy, Strong Governance and Significant Long-Term Value Creation Opportunity

Vector Science & Therapeutics Corp. Grants Options as Company Advances Growth Strategy

MEQUON, Wis., June 2, 2026 /PRNewswire/ -- Vector Science & Therapeutics (TSXV: PAIN) ("Vector" or the "Company") today announced that the Board of Directors...

Cingulate Provides Management Team Update

Jennifer Callahan, Chief Financial Officer, appointed Interim CEO

Pressure Sensitive Adhesive Tapes Market worth $92.41 billion by 2030 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., Aug. 15, 2025 /PRNewswire/ -- The report 'Pressure Sensitive Adhesive Tapes Market by Type (Single-Sided, Double-Sided), Adhesive Type (Acrylic, Rubber), Technology...

Pressure Sensitive Adhesive Tapes Market worth $92.41 billion by 2030 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., Aug. 15, 2025 /PRNewswire/ -- The report 'Pressure Sensitive Adhesive Tapes Market by Type (Single-Sided, Double-Sided), Adhesive Type (Acrylic, Rubber), Technology...

Milestone Scientific Schedules Second Quarter 2025 Financial Results and Business Update Conference Call

ROSELAND, N.J., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:00 AM Eastern Time on Friday, August 15th, 2025, to discuss the company’s financial results for the second quarter ended June 30, 2025, as well as the company’s corporate progress and other developments.

Daewoong Therapeutics Microneedle Patch Achieves Best-in-Class Bioavailability, Proving the Strength of Its Drug-Delivery Platform

More than 80% relative bioavailability compared with injectable obesity therapy, well above the roughly 30% reported for existing microneedle patches and setting a new...

Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

VICTORIA, British Columbia, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced its financial results for the second quarter of 2025 and provided a business update. All dollar values are in U.S. dollars unless stated otherwise.

WCC Biomedical@NACDS Total Store Expo: Advancing Microneedle Drug Delivery With WINMAP™ Platform

TAIPEI, Aug. 8, 2025 /PRNewswire/ -- WCC Biomedical, a leader in novel drug delivery systems, will attend the upcoming NACDS Total Store Expo (TSE), where...

METiS Technologies Closes RMB 400 Million Series D Financing to Power Beijing’s Biopharmaceutical Innovation Engine

BEIJING, China, Aug. 4, 2025 /PRNewswire/ -- METiS Technologies, a global leader in AI-driven nanodelivery innovation, today announced the successful completion of its RMB...

Raytone Biotech Announces First Patient Dosed in Clinical Trial of RTP-008 for Dry Eye Disease

BEIJING, Aug. 3, 2025 /PRNewswire/ -- Raytone Biotech, a clinical-stage biotechnology company dedicated to innovative ophthalmic therapies, announced that it successfully completed the first patient...

Raytone Biotech Announces First Patient Dosed in Clinical Trial of RTP-008 for Dry Eye Disease

BEIJING, Aug. 4, 2025 /PRNewswire/ -- Raytone Biotech, a biotechnology company dedicated to innovative ophthalmic therapies, announced that it successfully completed the first patient dosing...

First Subject Enrolled in Phase 1 Clinical Trial for Luye Pharma’s Investigational Antidepressant Targeting NET/DAT/GABAAR

SHANGHAI, Aug. 3, 2025 /PRNewswire/ -- Luye Pharma Group today announced that the first subject has been enrolled in a Phase 1 clinical trial in...

Suppositories Market Worth $2.05 billion by 2030 with 4.7% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., Aug. 1, 2025 /PRNewswire/ -- The global Suppositories Market, valued at US$1.56 billion in 2024 stood at US$1.63 billion in 2025 and...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDrug delivery

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers